Literature DB >> 30543595

Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Shannon L Maude1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30543595

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  12 in total

1.  CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.

Authors:  Holly L Pacenta; Theodore W Laetsch; Samuel John
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

2.  Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.

Authors:  Vanessa A Fabrizio; Jaap Jan Boelens; Audrey Mauguen; Christina Baggott; Snehit Prabhu; Emily Egeler; Sharon Mavroukakis; Holly Pacenta; Christine L Phillips; Jenna Rossoff; Heather E Stefanski; Julie-An Talano; Amy Moskop; Steven P Margossian; Michael R Verneris; Gary Douglas Myers; Nicole A Karras; Patrick A Brown; Muna Qayed; Michelle Hermiston; Prakash Satwani; Christa Krupski; Amy K Keating; Rachel Wilcox; Cara A Rabik; Vasant Chinnabhandar; Michael Kunicki; A Yasemin Goksenin; Crystal L Mackall; Theodore W Laetsch; Liora M Schultz; Kevin J Curran
Journal:  Blood Adv       Date:  2022-04-12

Review 3.  Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Cancers (Basel)       Date:  2019-02-06       Impact factor: 6.639

4.  GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.

Authors:  Franco Locatelli; Valentina Folgiero; Matteo Caforio; Cristina Sorino; Ignazio Caruana; Gerrit Weber; Antonio Camera; Loredana Cifaldi; Biagio De Angelis; Francesca Del Bufalo; Alessia Vitale; Bianca Maria Goffredo; Rita De Vito; Doriana Fruci; Concetta Quintarelli; Maurizio Fanciulli
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

5.  A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells.

Authors:  Matthias Bozza; Alice De Roia; Margareta P Correia; Aileen Berger; Alexandra Tuch; Andreas Schmidt; Inka Zörnig; Dirk Jäger; Patrick Schmidt; Richard P Harbottle
Journal:  Sci Adv       Date:  2021-04-14       Impact factor: 14.136

6.  Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.

Authors:  Vanessa A Fabrizio; Christine L Phillips; Adam Lane; Christina Baggott; Snehit Prabhu; Emily Egeler; Sharon Mavroukakis; Holly Pacenta; Jenna Rossoff; Heather E Stefanski; Julie-An Talano; Amy Moskop; Steven P Margossian; Michael R Verneris; Gary Douglas Myers; Nicole A Karras; Patrick A Brown; Muna Qayed; Michelle Hermiston; Prakash Satwani; Christa Krupski; Amy K Keating; Rachel Wilcox; Cara A Rabik; Vasant Chinnabhandar; Michael Kunicki; A Yasemin Goksenin; Kevin J Curran; Crystal L Mackall; Theodore W Laetsch; Liora M Schultz
Journal:  Blood Adv       Date:  2022-01-25

7.  Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.

Authors:  Hema Dave; Madeline Terpilowski; Mimi Mai; Keri Toner; Melanie Grant; Maja Stanojevic; Christopher Lazarski; Abeer Shibli; Stephanie A Bien; Philip Maglo; Fahmida Hoq; Reuven Schore; Martha Glenn; Boyu Hu; Patrick J Hanley; Richard Ambinder; Catherine M Bollard
Journal:  Blood Adv       Date:  2022-01-25

8.  EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations.

Authors:  Isabelle Beuchat; Husain H Danish; Daniel B Rubin; Caron Jacobson; Matthew Robertson; Henrikas Vaitkevicius; Jong Woo Lee
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

9.  Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Authors:  Ibrahim Yakoub-Agha; Christian Chabannon; Peter Bader; Grzegorz W Basak; Halvard Bonig; Fabio Ciceri; Selim Corbacioglu; Rafael F Duarte; Hermann Einsele; Michael Hudecek; Marie José Kersten; Ulrike Köhl; Jürgen Kuball; Stephan Mielke; Mohamad Mohty; John Murray; Arnon Nagler; Stephen Robinson; Riccardo Saccardi; Fermin Sanchez-Guijo; John A Snowden; Micha Srour; Jan Styczynski; Alvaro Urbano-Ispizua; Patrick J Hayden; Nicolaus Kröger
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

10.  Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.

Authors:  Vanessa A Fabrizio; Nancy A Kernan; Farid Boulad; Maria Cancio; Jennifer Allen; Meghan Higman; Steven P Margossian; Audrey Mauguen; Susan Prockop; Andromachi Scaradavou; Niketa Shah; Barbara Spitzer; Elliot Stieglitz; Nicholas Yeager; Richard J O'Reilly; Renier J Brentjens; Jaap Jan Boelens; Kevin J Curran
Journal:  Bone Marrow Transplant       Date:  2020-05-10       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.